Aerie Pharmaceuticals Logo

News & Presentations

UPCOMING EVENTS

There are currently no events to display.

CORPORATE PRESENTATIONS

Date Title Documents

Corporate Presentation - November 10, 2022

OIS Glaucoma Innovation Summit

OIS Retina Innovation Showcase

News Releases

Date Title and Summary Additional Formats
Toggle Summary Alcon Completes Acquisition of Aerie Pharmaceuticals, Inc., Strengthening Company’s Ophthalmic Pharmaceutical Business
Leveraging Alcon’s robust commercial capabilities and resources to drive further growth and access to Rocklatan   and Rhopressa Acquisition adds pharmaceutical research and development capabilities and further expertise for future product pipeline Expands Alcon’s presence in the $20 billion global
View HTML
Toggle Summary Aerie Pharmaceuticals Reports Third Quarter 2022 Financial Results
Third Quarter Glaucoma Franchise Net Revenues of $36.1 Million , up 23% over Third Quarter 2021 Previously Announced Agreement to be Acquired by Alcon; Transaction Expected to Close in the Fourth Quarter of 2022 DURHAM, N.C. --(BUSINESS WIRE)--Nov. 3, 2022-- Aerie Pharmaceuticals, Inc.
View HTML
Toggle Summary Aerie Pharmaceuticals to Host Key Opinion Leader Event on Dry Eye Disease: Current Landscape, Unmet Needs, and Emerging Treatment Options
Webinar to be held Friday, September 23, 2022   @   10 a.m. ET DURHAM, N.C. --(BUSINESS WIRE)--Sep. 13, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development, and commercialization of first-in-class ophthalmic therapies, today announced
View HTML
Toggle Summary Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Builds on Alcon’s existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment 1 Adds Rocklatan ® and Rhopressa ® , and a pipeline of several clinical and preclinical ophthalmic pharmaceutical product candidates Transaction values Aerie at approximately $770
View HTML
TOP